“…Despite many case reports and cohort studies, data from only 2 RCTs on antiviral treatment for cCMV have been published [ 12 , 13 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 ]. A phase III RCT, primarily assessing the hearing outcomes of newborns with cCMV, was conducted by the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group (CASG) [ 12 ].…”